Literature DB >> 24112890

Postoperative management of deep brain stimulation in Parkinson's disease.

Anna Castrioto1, Jens Volkmann, Paul Krack.   

Abstract

Deep brain stimulation has become an established treatment for advanced Parkinson's disease. Its postoperative management is a delicate phase, dedicated to finding the optimal balance between stimulation and dopaminergic treatment. Postoperative management can be divided into an acute phase, aimed at the selection of the best stimulation contact, and a stabilization phase, aimed at the progressive adjustment of stimulation parameters and medications. A good knowledge of the electrophysiological anatomy of the target and surrounding structures, of the potential consequences of dopaminergic treatment modifications, and of the time course and interactions between stimulation and medication effects is mandatory for optimal outcome. This chapter focuses on the main strategies for the acute and chronic management of stimulation parameters and medication in the three main nuclei targeted in Parkinson's disease, namely the subthalamic nucleus, the ventral intermediate thalamic nucleus, and the internal part of the globus pallidus.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Parkinson’s disease; deep brain stimulation; globus pallidus internus; subthalamic nucleus; ventrointermediate nucleus of the thalamus

Mesh:

Year:  2013        PMID: 24112890     DOI: 10.1016/B978-0-444-53497-2.00011-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  8 in total

1.  Machine Learning Approach to Optimizing Combined Stimulation and Medication Therapies for Parkinson's Disease.

Authors:  Reuben R Shamir; Trygve Dolber; Angela M Noecker; Benjamin L Walter; Cameron C McIntyre
Journal:  Brain Stimul       Date:  2015-06-15       Impact factor: 8.955

Review 2.  Troubleshooting Gait Disturbances in Parkinson's Disease With Deep Brain Stimulation.

Authors:  Nicoló G Pozzi; Chiara Palmisano; Martin M Reich; Philip Capetian; Claudio Pacchetti; Jens Volkmann; Ioannis U Isaias
Journal:  Front Hum Neurosci       Date:  2022-05-16       Impact factor: 3.473

Review 3.  Therapeutic Neurostimulation in Obsessive-Compulsive and Related Disorders: A Systematic Review.

Authors:  Nicola Acevedo; Peter Bosanac; Toni Pikoos; Susan Rossell; David Castle
Journal:  Brain Sci       Date:  2021-07-19

4.  Modeling of Electric Fields in Individual Imaging Atlas for Capsular Threshold Prediction of Deep Brain Stimulation in Parkinson's Disease: A Pilot Study.

Authors:  Matthieu Béreau; Astrid Kibleur; Walid Bouthour; Emilie Tomkova Chaoui; Nicholas Maling; T A Khoa Nguyen; Shahan Momjian; Maria Isabel Vargas Gomez; André Zacharia; Julien F Bally; Vanessa Fleury; Laurent Tatu; Pierre R Burkhard; Paul Krack
Journal:  Front Neurol       Date:  2020-07-02       Impact factor: 4.003

5.  Illness Representations and Coping Strategies in Patients Treated with Deep Brain Stimulation for Parkinson's Disease.

Authors:  Marc Baertschi; Nicolas Favez; João Flores Alves Dos Santos; Michalina Radomska; François Herrmann; Pierre R Burkhard; Alessandra Canuto; Kerstin Weber; Paolo Ghisletta
Journal:  J Clin Med       Date:  2020-04-21       Impact factor: 4.241

Review 6.  Opportunities of connectomic neuromodulation.

Authors:  Andreas Horn; Michael D Fox
Journal:  Neuroimage       Date:  2020-07-20       Impact factor: 6.556

Review 7.  Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.

Authors:  Thomas J C Zoon; Geeske van Rooijen; Georgina M F C Balm; Isidoor O Bergfeld; Joost G Daams; Paul Krack; Damiaan A J P Denys; Rob M A de Bie
Journal:  Mov Disord       Date:  2020-12-16       Impact factor: 10.338

8.  Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.

Authors:  Massiva Sayad; Mohamed Zouambia; Malika Chaouch; Farida Ferrat; Mustapha Nebbal; Mohamed Bendini; Suzanne Lesage; Alexis Brice; Mohamed Brahim Errahmani; Boualem Asselah
Journal:  BMC Neurosci       Date:  2016-02-01       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.